sameAs
A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic LeukemiaBendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaA Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's LymphomaA Study to Assess the Effect of Rifampin on the Metabolism of ABT-199A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage ACYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLVenetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin LymphomaVenetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AMLIbrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLA Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical PracticeRituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLLA Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaA Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaVenetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell LymphomaVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsVenetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell LymphomaA Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesCytarabine, Idarubicin, Liposome-encapsulated Daunorubicin-Cytarabine or Decitabine in Treating Older Patients With Acute Myeloid LeukemiaA Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 AberrationsA Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyVenetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaA Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaLiposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaVenetoclax RegistryVenetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPNVenetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid LeukemiaRituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCLA Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaVenetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaVenetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaA Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination TherapyStudy Venetoclax Effectiveness and Real‐Life Treatment Management in Participants With Chronic Lymphocytic LeukemiaVenetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALLA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple MyelomaA Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaA Safety and Pharmacokinetics (PK) Study of Venetoclax in Participants With Non-Hodgkin's LymphomaStudy to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical PracticeA Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell
P4844
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaHuman Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cellsABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.ABT-199 for chronic lymphocytic leukemia.Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).Targeting the Bcl-2 Family in B Cell LymphomaTargeting Oxidative Stress With Auranofin or Prima-1 to Circumvent p53 or Bax/Bak Deficiency in Myeloma CellsRelapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemiaVenetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseThe Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic SyndromeShedding Light on the Interaction of Human Anti-Apoptotic Bcl-2 Protein with Ligands through Biophysical and in Silico StudiesA Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.ABT-199 shows effectiveness in CLLABT-199 partners with azacitidine to contest myeloid malignanciesCorrection: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell LymphomaVenetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies
P921
Q1088156-99BBA508-4B3A-47DA-B0A0-127A8E8476C5Q1088156-EB7D8B70-B58A-4161-80E8-32830630AAFFQ1138590-CD77B9B7-8E9F-4796-A739-553F30103D90Q2626074-4D12560D-1EA7-4162-BC86-C4CC2A531D07Q264118-26A858B6-E009-4E1E-A11C-D5A96AF7BD8AQ268713-7FBBBBFD-9EE7-4FB1-B28E-06BAD4335E60Q4833719-FAF4DB72-9693-4958-80B7-D1CF7FE1CBDCQ954625-E0228432-C4C3-4BE2-A86F-D5181401C2C1
P2176
Q61864716-C173A59E-6626-4CBA-8569-3FE45E2FCC66Q61906943-8E36BE35-56A1-401A-BC26-6D2D2E5A4EFEQ61969737-930A4255-B34E-4596-BE47-DC79AA9C0BB7Q61975414-6DF46406-C074-484C-B2F6-682EF4D5BEF5Q61975415-927EB253-24E3-44CE-B414-41D98B4331F8Q61975416-940FF26B-071A-4F38-9E2D-09D458FA1451Q62031687-080FEF83-3555-404E-86D1-E5DA3451F2DFQ62035110-EEC706E3-D012-44CA-B898-D95445BA0DE8Q62041423-51AF054E-6C65-498F-BB48-189F53FB3394Q62042204-DF3B443A-0E53-4782-B089-2BD2133598B8Q62042586-B882A0D9-7E52-42E2-B3B7-CBF13F38DA6FQ62062441-79053A4C-8B21-419E-815C-07ADBB95F387Q62063038-E2656598-36B7-4983-B75B-1E079A0DE77CQ62809913-9B5E5364-22E9-4941-8E6F-7F4F0BA49BB4Q62812512-B98E777C-1991-4750-9D78-2A38F6DCFF07Q62815009-2A759CE2-6057-4F75-81F2-A453C5670024Q62819144-997E8891-DCAC-456A-B863-DCDA7ABB00DBQ62823205-53F3FD5D-E643-4297-94F7-79FB62C6089CQ63011135-506A720B-1C25-41C8-9B8F-F8E0F7E5949BQ63013620-2B74CCAA-59DD-4760-9331-82C2DC453FC9Q63013648-BBAF858E-877D-43D8-BEEB-F60753BC81DBQ63229185-1A78A832-61B5-450C-BD5A-4677C7F699D9Q63229581-D12A2011-F95F-40BD-9494-A6FCC630B961Q63338484-10AF6AF7-5B53-498B-8371-2B6E7A48EE40Q63393186-55C0537D-68B9-441A-81AD-84656F7728C9Q63393687-2EF2E66D-7B52-4D6A-9A54-0AF67AC8C66AQ63394044-E11F6FC0-5BEA-4B77-A290-BBABAF33ACE8Q63397091-EA7067F8-61AD-4699-A3E9-F0235E80627EQ63397866-05C1268A-8721-47B4-8190-9B8F71E577F5Q63397909-4BEADD33-955E-4B24-A459-5D9A49675514Q63397941-B750B075-6291-4B05-83AB-73458C83012CQ63402393-85E5C4ED-35DC-4DC3-8B49-EF663A15C8A8Q63404511-171F7EDB-A086-4EB7-AEDC-888C39883123Q63405167-C7E2397A-6A47-4F4E-8D8C-E91FD4128A4BQ63534969-90F1BAC9-20E5-477D-A97C-341767DC8BCEQ63571014-3F90D4AF-F649-4C19-9208-A5F4C7428F3DQ63571415-2707E294-6170-42E0-9EE8-BAC56495EA1FQ63571492-939EC7BB-076D-463E-ACDF-564ABF055671Q63572007-DBB70848-8283-4183-AF74-1539C1C73C8CQ63572888-7AE8BDBF-EC67-4021-BE38-B42B7A4BA9FC
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Venetoclax
@de
venetoclax
@en
venetoclax
@es
venetoklaks
@nn
vénétoclax
@fr
Венетоклакс
@ru
فينيتوسلاكس
@ar
ベネトクラクス
@ja
type
label
Venetoclax
@de
venetoclax
@en
venetoclax
@es
venetoklaks
@nn
vénétoclax
@fr
Венетоклакс
@ru
فينيتوسلاكس
@ar
ベネトクラクス
@ja
altLabel
4-{4-[(4'-chloro-5,5-dimethyl[ ...... 3-b]pyridin-5-yl)oxy]benzamide
@en
ABT-199
@en
GDC-0199
@en
Venclexta
@en
venetoclax
@en
prefLabel
Venetoclax
@de
venetoclax
@en
venetoclax
@es
venetoklaks
@nn
vénétoclax
@fr
Венетоклакс
@ru
فينيتوسلاكس
@ar
ベネトクラクス
@ja
P2175
P486
P592
P6366
P661
P662
P683
P117
P2067
867.318096
P2115
N0000192521
P2175
P231
1257044-40-8
P232
P233
CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl) ...... =O)[O-])OC7=CN=C8C(=C7)C=CN8)C
P234
1S/C45H50ClN7O7S/c1-45(2)15-11 ...... ,29H2,1-2H3,(H,47,49)(H,50,54)
P235
LQBVNQSMGBZMKD-UHFFFAOYSA-N
P2566
100.254.611